Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes

Science

Volumn 280, Issue 5370, 1998, Pages 1750-1752

  Shen, Hong Ming ^a   Peters, Andrew ^a   Baron, Beverly ^a   Zhu, Xiangdong ^a   Storb, Ursula ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CD19 ANTIGEN; DNA; IMMUNOGLOBULIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M;

ARTICLE; B LYMPHOCYTE; BASE PAIRING; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; HUMAN; HUMAN CELL; MEMORY CELL; NORMAL HUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION; TATA BOX; TRANSCRIPTION INITIATION;

ADULT; ALPHA-FETOPROTEINS; B-LYMPHOCYTES; CLONING, MOLECULAR; DNA-BINDING PROTEINS; FEMALE; GENES, IMMUNOGLOBULIN; GENES, MYC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOLOGIC MEMORY; INTRONS; MALE; MIDDLE AGED; MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; RIBOSOMAL PROTEINS; TATA BOX; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 2642623612     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.280.5370.1750     Document Type: Article

References (31)

1. U. Storb, in The Biology of Germinal Centers in Lymphoid Tissues, G. J. T. and V. K. Tsiagbe, Eds. (Landes, Austin, TX, in press).
2. A. Peters and U. Storb, Immunity 4, 57 (1996).
3. U. Storb, Curr. Opin. Immunol. 8, 206 (1996).
4. A. Betz et al., Cell 77, 239 (1994).
5. K. Tumas-Brundage and T. Manser, J. Exp. Med. 185, 239 (1997).
6. E. Klotz and U. Storb, J. Immunol. 157, 4458 (1996).
7. + B cells (Table 1) are unlikely to have undergone somatic mutation.
8. B cells were pelleted and resuspended, and one volume of 2X DNA lysis buffer [proteinase K (1 mg/ml), 100 mM EDTA (pH 8.0), 2% SDS, and 100 mM tris (pH 8.0)] was added. The lysate was incubated at 37°C overnight. DNAs were extracted twice with phenol and then twice with phenol/chloroform/isoamyl alcohol (25:24:1). DNAs were precipitated with ethanol, pelleted, and dissolved in distilled water.
9. We used the following primers: BCL-6 gene primers, 5′-GCTCTAGACCGCTGCTCATGATCATTAT-TT(sense), 5′-CGGGGTACCTAGACACGATACT-TCATCTCAT (antisense) or 5′-CCGCTGCTCAT-GATCATTATTT (sense), 5′-TAGACACGATACT-TCATCTCAT (antisense); c-MYC gene primers, 5′-CCGGTACCCTTGCCGCATCCACGAAACTTT (sense), 5′-GCTCTAGAGACCCAGGTTTTA (antisense); S14 gene primers, 5′-CGGGGTACCCGG-GACAGACGTGGGCTCCCG (sense), GCTCTAG-ATCTAAGGGAGAGAGAAACTGAC (antisense); AFP gene primers, 5′-GGATGAATGGTTTGTA-TGTTTC (sense), GGTTTGACTCATGAGATTTC (antisense). PCR conditions for BCL-6, c-MYC, and AFP were 94°C for 5 min, 57°C for 30 s, 75°C for 1 min, 1 cycle; 94°C for 30 s, 57°C for 30 s, 75°C for 1 min, 29 cycles; and 75°C for 6 min, 1 cycle. PCR conditions for S14 were 95°C for 5 min, 67°C for 30 s, 75°C for 1 min, 1 cycle; 95°C for 30 s, 67°C for 30 s, 75°C for 1 min, 29 cycles; and 75°C for 6 min, 1 cycle.
10. R. Taub et al., Cell 36, 339 (1984).
11. J. Mueller, S. Janz, J. Goedert, M. Potter, C. Rabkin, Proc. Natl. Acad. Sci. U.S.A. 92, 6577 (1995).
12. BCL-6 DNA fragments from memory B cells were inserted into pBluescript KS at Kpn I and Xba I sites, and the other gene fragments and BCL-6 from naive B cells were inserted into the Srf I site in pBluescript SK according to manufacturer's instructions (Strategene). Plasmids with the inserts were transformed into Escherichia coli JH3.
13. Automated sequencing was done for all amplified gene fragments. Manual sequencing was performed to confirm some mutations. Sequences were aligned with the data from GenBank and (25) by MacVector4.14 to find mutations.
14. 5 bp per cycle (26). Thus, for 30 cycles, roughly one mutation in 26,000 bp would be expected.
15. Compared with the GenBank sequences, many changes were seen in BCL-6 in all four donors and in S14 donor A.
16. U. Storb et al., Curr. Top. Microbiol. Immunol. 229, 11 (1998).
17. H4 family genes were sequenced from positions 130 to 296 of V. Seven of the nine genes were mutated with 5 to 24 mutations per 167 nucleotides.
18. A. Migliazza et al., Blood 90 (suppl. 1, pt. 1), 177a (1997).
19. T. Rabbits, A. Forster, P. Hamlyn, R. Baer, Nature 309, 592 (1984).
20. A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995).
21. N. Hariharan D. Kelley, R. Perry, Genes Dev. 3, 1789 (1989).
22. J. Newton et al., Eur. J. Immunol. 26, 811 (1996).
23. U. Storb et al., in preparation.
24. U. Klein, R. Kueppers, K. Rajewsky, J. Exp. Med. 180, 1383 (1994).
25. F. Bernardin et al., Oncogene 14, 849 (1997).
26. J. Cline, J. Braman, H. Hogrefe, Nucleic Acids Res. 24, 3546 (1996).
27. D. D. Rhoads, A. Dixit, D. J. Roufa, Mol. Cell. Biol. 6, 2774 (1986).
28. P. E. M. Gibbs, R. Zielinski, C. Boyd, A. Dugaiczyk, Biochemistry 26, 1332 (1987).
29. W. W. Colby, E. Y. Chen, D. H. Smith, A. D. Levinson, Nature 301, 722 (1983).
30. C. Gazin et al., EMBO J. 3, 383 (1984).
31. Supported by NIH grant GM38649 to U.S. A.P. was partly supported by NIH training grant GM07183. We thank T. McKeithan, T. E. Martin, N. Michael, and P. Engler for critical reading of the manuscript.